Display options
Cite
Gai XD, Wu WF. Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis. Exp Ther Med. 2017;14(4):3908-3914doi: 10.3892/etm.2017.4963.
Gai, X. D., & Wu, W. F. (2017). Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis. Experimental and therapeutic medicine, 14(4), 3908-3914. https://doi.org/10.3892/etm.2017.4963
Gai, Xiao-Dong, and Wu, Wei-Feng. "Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis." Experimental and therapeutic medicine vol. 14,4 (2017): 3908-3914. doi: https://doi.org/10.3892/etm.2017.4963
Gai XD, Wu WF. Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis. Exp Ther Med. 2017 Oct;14(4):3908-3914. doi: 10.3892/etm.2017.4963. Epub 2017 Aug 18. PMID: 29043000; PMCID: PMC5639355.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2017 Oct;14(4):3908-3914. doi: 10.3892/etm.2017.4963. Epub 2017 Aug 18.

Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis.

Experimental and therapeutic medicine

Xiao-Dong Gai, Wei-Feng Wu

Affiliations

  1. The Second Department of Liver Medicine, The Second Affiliated Hospital of Southeast University, Nanjing, Jiangsu 210003, P.R. China.

PMID: 29043000 PMCID: PMC5639355 DOI: 10.3892/etm.2017.4963

Abstract

Chronic hepatitis B virus (CHB) infection is a burden on global healthcare and is associated with a higher risk of serious sequelae, including cirrhosis and hepatocellular carcinoma. The clinical application of entecavir as a treatment for CHB has produced positive outcomes, and so is an attractive form of pharmacological therapy. However, little data exists comparing the safety and efficacy of entecavir for the treatment of hepatitis B virus (HBV)-related compensated, and decompensated cirrhosis, respectively. The aim of the present study was to evaluate entecavir therapy as a treatment for patients with HBV-related compensated and decompensated cirrhosis. A retrospective analysis of 46 compensated patients (compensated group) and 51 decompensated cirrhotic patients (decompensated group) treated with entecavir was conducted. Baseline demographics, clinical outcomes, and adverse events during the treatment were compared. Treatment with entecavir for 96 weeks resulted in significant improvements in serum levels of HBV DNA (P=0.002), albumin (P=0.014), cholinesterase (CHE; P=0.001), HBV DNA negativity rate (P=0.004), Child-Turcotte-Pugh score (P=0.030), alanine aminotransferase normalized rate (P=0.039), and the degree of esophageal varices liver stiffness (P=0.002) in the two groups. However, statistical analysis revealed that the improvements were significantly higher in the compensated group compared with the decompensated group (P<0.05). The complement component (C)3 and C4 levels were also significantly increased in the compensated group compared with the decompensated group at weeks 24, 48 and 96 (P<0.05). In addition, the incidences of hepatocellular carcinoma, upper digestive tract hemorrhage and ascites were significantly higher in the decompensated group compared with the compensated group (P<0.05). In conclusion, treatment with 96-week entecavir therapy produced similar clinical outcomes in compensated and decompensated cirrhotic patients via inhibiting HBV-DNA viral load and recovering complement C3 and C4; however, entecavir exerts a better effect on patients with compensated cirrhosis, and so this therapy may improve the prognosis of such patients.

Keywords: cirrhosis; complement; efficacy; entecavir; hepatitis B virus

References

  1. Int J Clin Exp Med. 2015 Dec 15;8(12):22204-16 - PubMed
  2. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4057-66 - PubMed
  3. Int J Clin Exp Pathol. 2015 Sep 01;8(9):11680-4 - PubMed
  4. Mediators Inflamm. 2015 ;2015 :535938 - PubMed
  5. Hepatol Int. 2016 Nov;10 (6):924-936 - PubMed
  6. Clin Gastroenterol Hepatol. 2011 Mar;9(3):274-6 - PubMed
  7. Zhonghua Gan Zang Bing Za Zhi. 2016 Jun;24(6):469-73 - PubMed
  8. Eur J Gastroenterol Hepatol. 2014 Apr;26(4):396-403 - PubMed
  9. J Clin Gastroenterol. 2011 May-Jun;45(5):449-55 - PubMed
  10. J Dig Dis. 2016 Aug;17 (8):538-546 - PubMed
  11. Hepatology. 2011 Jan;53(1):62-72 - PubMed
  12. Clin Exp Med. 2017 May;17 (2):233-241 - PubMed
  13. MMW Fortschr Med. 2011 Mar 31;153(13):22-3 - PubMed
  14. Aliment Pharmacol Ther. 2016 Aug;44(4):380-9 - PubMed
  15. Hepatol Res. 2017 Mar;47(3):E161-E168 - PubMed
  16. Int J Clin Exp Med. 2015 Nov 15;8(11):21062-70 - PubMed
  17. Hepat Mon. 2015 Aug 30;15(8):e29183 - PubMed
  18. Clin Gastroenterol Hepatol. 2012 May;10(5):527-34.e1-2 - PubMed
  19. World J Gastroenterol. 2015 Jul 7;21(25):7869-76 - PubMed
  20. World J Gastroenterol. 2015 Aug 28;21(32):9598-606 - PubMed
  21. J Viral Hepat. 2013 Apr;20 Suppl 1:58-64 - PubMed
  22. Med Clin North Am. 2009 Jul;93(4):787-99, vii - PubMed
  23. N Engl J Med. 2004 Oct 7;351(15):1521-31 - PubMed
  24. World J Surg. 2015 Nov;39(11):2764-70 - PubMed
  25. Medicine (Baltimore). 2016 Apr;95(16):e3372 - PubMed
  26. Eur J Gastroenterol Hepatol. 2013 Dec;25(12):1369-76 - PubMed
  27. Hum Pathol. 2009 Oct;40(10):1365-76 - PubMed
  28. World J Gastroenterol. 2013 Jun 14;19(22):3481-6 - PubMed
  29. Aliment Pharmacol Ther. 2014 Mar;39(5):532-9 - PubMed
  30. Korean J Gastroenterol. 2012 Mar;59(3):224-31 - PubMed
  31. Int J Clin Exp Pathol. 2015 Nov 01;8(11):15260-4 - PubMed
  32. Int J Clin Exp Med. 2015 Dec 15;8(12):22167-74 - PubMed
  33. Cell Physiol Biochem. 2016;40(1-2):370-378 - PubMed
  34. Biomed Res Int. 2016;2016:3524842 - PubMed
  35. Int J Mol Sci. 2016 May 25;17 (6): - PubMed

Publication Types